131 related articles for article (PubMed ID: 8930784)
1. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
[TBL] [Abstract][Full Text] [Related]
2. An open trial of buspirone added to neuroleptics in schizophrenic patients.
Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.
Dockens RC; Salazar DE; Fulmor IE; Wehling M; Arnold ME; Croop R
J Clin Pharmacol; 2006 Nov; 46(11):1308-12. PubMed ID: 17050795
[TBL] [Abstract][Full Text] [Related]
4. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of buspirone extended-release tablets: a single-dose study.
Sakr A; Andheria M
J Clin Pharmacol; 2001 Jul; 41(7):783-9. PubMed ID: 11452712
[TBL] [Abstract][Full Text] [Related]
6. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state.
Buch AB; Van Harken DR; Seidehamel RJ; Barbhaiya RH
J Clin Pharmacol; 1993 Nov; 33(11):1104-9. PubMed ID: 8300893
[TBL] [Abstract][Full Text] [Related]
7. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.
Barbhaiya RH; Shukla UA; Greene DS; Breul HP; Midha KK
J Clin Psychopharmacol; 1996 Feb; 16(1):26-34. PubMed ID: 8834415
[TBL] [Abstract][Full Text] [Related]
8. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
[TBL] [Abstract][Full Text] [Related]
9. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
10. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
[TBL] [Abstract][Full Text] [Related]
11. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
[TBL] [Abstract][Full Text] [Related]
12. No interaction between desipramine and bromperidol.
Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
[TBL] [Abstract][Full Text] [Related]
13. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of buspirone following oral administration to rhesus monkeys.
Marathe PH; Shen F; Markham P; Greene DS
J Pharm Pharmacol; 1999 May; 51(5):601-7. PubMed ID: 10411220
[TBL] [Abstract][Full Text] [Related]
15. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Uematsu T; Matsuno H; Sato H; Hirayama H; Hasegawa K; Nakashima M
J Pharm Sci; 1992 Oct; 81(10):1008-11. PubMed ID: 1432610
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
Jagannathan V; Venitz J
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of buspirone in autistic children.
Edwards DJ; Chugani DC; Chugani HT; Chehab J; Malian M; Aranda JV
J Clin Pharmacol; 2006 May; 46(5):508-14. PubMed ID: 16638734
[TBL] [Abstract][Full Text] [Related]
20. Systemic absorption of amitriptyline and buspirone after oral and transdermal administration to healthy cats.
Mealey KL; Peck KE; Bennett BS; Sellon RK; Swinney GR; Melzer K; Gokhale SA; Krone TM
J Vet Intern Med; 2004; 18(1):43-6. PubMed ID: 14765730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
